What is BioFlyte?
BioFlyte is at the forefront of developing revolutionary fieldable biological contamination sampling, detection, and identification solutions. The company's technology is designed to address critical needs in infrastructure protection and pandemic response. By commercializing a novel class of detection systems, BioFlyte aims to provide rapid and accurate identification of biological threats, thereby enhancing national security and public health preparedness. The firm's focus on deep technology and patent-based innovation positions it as a key player in the biodefense sector.
How much funding has BioFlyte raised?
BioFlyte has raised a total of $12.8M across 3 funding rounds:
Angel/Seed
$1.3M
Series A
$6.1M
Series B
$5.4M
Angel/Seed (2020): $1.3M with participation from Anzu Partners LLC
Series A (2022): $6.1M led by Cottonwood Technology Fund and Anzu Partners
Series B (2023): $5.4M supported by Scout Ventures and Cottonwood Technology Fund
Key Investors in BioFlyte
Scout Ventures
Scout Ventures is an early-stage venture capital firm that invests in frontier technologies, focusing on making the world safer. They provide expertise in business development, hiring, and sales strategies to support companies in sectors like AI, robotics, and advanced materials.
Cottonwood Technology Fund
Cottonwood Technology Fund is an early-stage venture capital fund specializing in patent-based hard science and deep tech startups, particularly in photonics, nanotechnology, and advanced materials. They provide capital and business development support to help companies grow from research to significant market impact.
Anzu Partners
Anzu Partners is an investment firm focused on breakthrough technologies in clean tech, industrial, and life sciences sectors. They offer capital and strategic support, leveraging a team of operators, scientists, and engineers to help founders bring innovative solutions to market.
What's next for BioFlyte?
The substantial enterprise-level funding and recent strategic investment indicate BioFlyte is poised for significant scaling and market expansion. This capital infusion will likely accelerate product development, enhance manufacturing capabilities, and broaden the company's go-to-market strategy. With a clear focus on critical infrastructure protection and pandemic response, BioFlyte is well-positioned to capitalize on growing global demand for advanced biodefense technologies. Future growth may involve strategic partnerships and further technological advancements to maintain its competitive edge in this vital industry.
See full BioFlyte company page
